



(OTCQB: ZIVO)

Transformative Opportunities in Therapeutics & Nutrition

January 2025



SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Some of the statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to statements regarding:

- The Company's ability to raise the funds we need to continue our operations;
- The Company's goal to begin to generate revenues and become profitable;
- Regulation of our products;
- Market acceptance of our products and derivatives thereof;
- The results of current and future testing of our products;
- The anticipated performance and benefits of our product;
- The Company's ability to expand its intellectual property;
- The Company's ability to enter into strategic partnerships;
- The Company's ability to generate licensing fees; and
- The Company's financial condition or results of operations

In some cases, you can identify forward-looking statements by terms such as "may", "will", "should", "could", "would", "expects", "plans", "anticipates", "believes", "estimates", "projects", "predicts", "potential" and similar expressions intended to identify forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this presentation to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. We qualify all of our forward-looking statements by these cautionary statements.

THE INFORMATION IN THIS PRESENTATION IS PROVIDED TO YOU SOLELY FOR INFORMATIONAL PURPOSES AND IS NOT AN OFFER TO BUY OR SELL, A SOLICITATION OF AN OFFER TO BUY OR SELL, ANY SECURITY OR INSTRUMENT OF THE COMPANY, OR TO PARTICIPATE IN ANY INVESTMENT ACTIVITY OR TRADING STRATEGY.



One Natural Source. Numerous Commercial Opportunities.

Developing novel therapeutics and functional food ingredients to power immune health



Currently Generating Revenue

- Direct-to-consumer launch of Zivolife™, a nutritional supplement for the human green powder and vegan protein markets



Longer-term Valuation Drivers

- Published studies support active therapeutics pipeline addressing billion-dollar opportunities in animal and human treatments through the immune system and other novel pathways



Robust and Versatile Products

- Numerous commercial applications in animal and human pharmaceuticals, food, dietary supplements, nutraceuticals and cosmetics

- ✓ Patent-pending for use as an immune modulating candidate that may establish a new class of therapeutic products
- ✓ Potential for numerous therapeutic applications across three global mega-markets: human, livestock and companion animals



One common natural technology, two value creating paths

Alpine lake water, rich in micro-organisms and various types of algae species, brought to the U.S., termed "Lebenszeit" and used as a home remedy

1980-2003: Additional fermentation step added to Lebenszeit and the water product is marketed as ProAlgaZyme.

Zivo Bioscience characterizes and registers Klebsormidium var. ZIVO.

2022 – 2024: Commercial cultivation development begins in late 2022 and reaches commercial scale cultivation in outdoor ponds in the high desert of Peru in first half of 2024

- Cultivation techniques improved
- Commercial scale manufacturing in place

Zivolife™ product begins commercial direct-to-consumer sales via www.zivo.life.

1930s

1980

2003

2016

2021

2022

2024

2023

2024

2025

2003 - 2016: Zivo Bioscience, Inc. (ZIVO) acquires the technology.

- ProAlgaZyme removed from the market
- Lab experiments for therapeutic benefits on various species
- ZIVO applies the scientific method and undertakes to purify, isolate, and characterize the product's beneficial components.

2016-2021: Zivo confirms product safety under GRAS for dried algae.

Leverages earlier studies and identifies therapeutic opportunities in various animal species - prioritizes target markets

2022

Initiated studies to determine optimal first indication target for therapeutic components immune-modulating product

Coccidiosis treatment evaluated in confirmatory study in broiler chickens

Real-world coccidiosis treatment studies with global animal pharma partners

Preliminary results in combatting avian influenza

Nutrition

Therapeutic



Nutrition

- Growth and distribution of Zivolife™, ZIVO's proprietary whole algal biomass, for use as a food or food ingredient to leverage its unique nutritional values
- The identified components of ZIVO's algae lead to many potential structure-function claims for nutrition and enhancement of overall health
- Retail product launched through our distributor, demand is exceeding supply



Therapeutics

- Identification and development of extracts, fractions or molecules derived from proprietary algal polyculture
- For use in treating disease or other health conditions in humans and in animals
- Protected by patents, trade secrets and know-how
- Plan to monetize through licensings, joint ventures or other structures to leverage established manufacturing and sales and distribution of end products.



Nutrition: Zivolife™ – Proprietary Algal Biomass

Our first revenue-generating, commercially-available product

\$1.0 billion market by 2031

Global green powder market

Background

- ✓ Zivolife is natural, non-GMO, and a source of plant-based protein, naturally occurring beta glucan and fiber
- ✓ Sustainable, whole-food product that delivers a wide range of nutrients contributing to overall health

Growing Market

- ✓ Rapid growth in demand for plant-based protein sources being driven by trends in healthy living, environmental sustainability and ethical considerations, market expected to grow at 13.4% CAGR through 2031

Revenue Generation

- ✓ Premium product. Zivolife product produced in first 18 months contractually committed for purchase by our distributor

Scale Up

- ✓ Collaboration with Alimenta Algae SAC to repurpose prior microalgae facility, to reach full capacity in 2026



Dairy Free



GMO Free



Gluten Free



Vegan



Nutrition: Committed Revenue Stream Grows with Scale

24,000 kg annual purchase commitment¹


ZWorldwide is ZIVO's global distribution partner, with an initial focus on North America

- ✓ Commits to minimum annual volume purchases for 5 years
- ✓ ZWorldwide to purchase entire Zivolife supply for initial 18 months
- ✓ Annual commitment includes at least 24,000 kg of Zivolife

Scaling Plans to Meet Growing Demand

- ✓ Collaboration with Alimenta Algae SAC to convert development facility to commercial production
- ✓ Facility capable of producing up to 100,000 kg annually
- ✓ Planned to operate at full capacity by Q4 of 2026

Algae production pond scaling plans



¹ The purchase commitment is per year for 5 years, may be limited by production capacity



Nutrition: Significant Market Opportunity

Proprietary dried algal biomass as a food or food ingredient



Nutritive compounds found in ZIVO algae include functional food ingredients proven to enhance overall health in humans

Cultivation Model

- ✓ Presently growing in commercial-scale cultivation ponds in central Peru with low startup cost, sustainability, high yield and continuous harvest
- ✓ We have optimized the production process for commercial product and now have the opportunity to implement larger facilities
- ✓ Multiple cultivation options exist (e.g., open ponds, photo bioreactors); important as we look for additional growers

Product Versatility

- ✓ Significant levels of protein, micronutrient and non-starch polysaccharides
- ✓ Ease of post-processing, utilize mostly industry-standard equipment
- ✓ Low taste and odor, takes flavorings well
- ✓ Cooperates well with other wet and dry ingredients
- ✓ Shelf stable, does not require refrigeration



Market Opportunity

\$1.0 billion by 2031

Green powder nutritional market

\$6.3 billion in 2021

Protein supplement market (global)





Nutrition: Additional Nutritional Opportunities

ZIVO will develop algae-based products to address other food, supplement, and cosmetic markets

Geographic Expansion

- Canada
- Europe
- ROW

Ingredient in other green powders

Adjacent Markets

Cosmetics / Topicals

- Serums / Creams
- Cleansers
- Gommage / Masks
- Spa treatments

Cosmeceuticals



Food or Supplement Ingredient

Health Foods

Dry

- Health Bars
- Granola Mixes

Liquid

- Smoothie mix consumer or restaurant
- Drinks
- Teas

Snack Foods

Healthy versions of tortilla chips, pretzels, etc.

Other Foods

Baby food
Breads and baked goods
Dry mixes (cake, pancake, muffin, etc)

- ✓ Monetization via partnering with established food and nutrition supplement companies
- ✓ Joint develop agreements, as needed



Therapeutic: Significant Market Opportunity

Biopharma products from Zivo proprietary assets feature broad therapeutic potential in animals and humans.



Initial Commercial Application

- ✓ Coccidiosis treatment designed to be introduced in poultry feed or drinking water - IP protected via global patents
- ✓ Study results show our product candidate as a replacement for antibiotics, ionophores and other chemical-based therapies
- ✓ Aligned with evolving industrywide expectations for a non-antibiotic approach and supports a commitment to providing safer and more sustainable solutions for animal health and the human food supply
- ✓ Our product candidate will be regulated for use through the USDA's Center for Veterinary Biologics
- ✓ Joint development agreement and/or license negotiations are in process
- ✓ Successes in poultry led us to evaluate our product as a treatment for Avian Influenza



Market Overview

\$15 billion

Worldwide annual cost of coccidiosis in poultry

\$5.8 billion by 2027

Worldwide animal antimicrobials market

\$753M in 2020 → \$1.1B by 2025

Global feed phytogenic market size growth

\$14.6B in 2020 → \$23.9B by 2028

Global animal growth promoters and performance enhancers market size growth



Therapeutic: Validated Efficacy as Coccidiosis Treatment


More than 20 independent research trials to evaluate the efficacy of ZIVO's bioactive compounds in the treatment of coccidiosis have been completed

Validated efficacy and mechanism-of-action studies in poultry gut health


- ✓ Minimize or eliminate the negative effects of coccidiosis on the broiler chickens by numerous measures of gut health and overall well-being
- ✓ Reduced mortality
- ✓ Enhanced feed conversion, growth and body weight via increased nutrient uptake
- ✓ Reduce the incidence of Campylobacter, Salmonella, E. coli, and Clostridium perfringens (all significant sources of food-borne illness) in the digestive tract of broiler chickens in the absence of antibiotics or other antimicrobial compounds

Healthier Birds, Higher Profits, Without Antibiotics/Ionophores/Chemicals


Body Weight




Feed Cost



Mortality



Intestinal Damage



Proprietary active ingredients were evaluated in a trial for efficacy in mitigating the effects of **Low Pathogenicity Avian Influenza (LPAI)**



Key findings of statistical significance from the study include:

- ✓ **Reduction in viral titers** (viral shedding) in infected birds receiving ZIVO's products compared with untreated infected controls.
- ✓ **Delay in transmission of LPAI** when healthy birds were exposed to infected birds, suggesting a slower and less aggressive spread of disease.

ZIVO's proprietary active ingredients represent the potential opportunity in:


- ✓ **Reducing the spread of LPAI in commercial poultry operations**
- ✓ **Enhancing overall flock health**

Next steps:

- ☐ Additional research & development with university and commercial partners
- ☐ Supports ZIVO's pipeline to address a broad spectrum of viral challenges in poultry industry

ZIVO will expand products/technology into other therapeutic opportunities, and employ a business model to license proprietary molecules or bioproducts to monetize its intellectual property portfolio

Poultry Other (Livestock)	Porcine (Livestock)	Bovine (Livestock)	Canine (Companion)	Human
Therapeutic Opportunities <ul style="list-style-type: none"> • Avian flu • Necrotic enteritis • Foodborne gut pathogens 	Therapeutic Opportunities <ul style="list-style-type: none"> • Respiratory disease • Digestive health 	Therapeutic Opportunities <ul style="list-style-type: none"> • Mastitis 	Therapeutic Opportunities <ul style="list-style-type: none"> • Joint health 	Therapeutic Opportunities <ul style="list-style-type: none"> • Joint health • Anti-aging / Skin health • Sepsis



Due to the nature of the IP and the various applications, ZIVO may plan to develop individual licenses for each application in each target species



Recent Developments and Strategic Progress

Advancements in Coccidiosis Treatment:

January 2024: **Positive efficacy results from a 42-day validation study** demonstrated the effectiveness of ZIVO's non-antibiotic, immune-modulating product candidate in preventing and treating coccidiosis in broiler chickens.

February 2024: Additional findings revealed a **significant reduction in intestinal damage** among treated chickens, leading to **optimized feed utilization and improved feed conversion ratios**.

Progress in Licensing Opportunities:

December 2024: ZIVO reported substantial progress in licensing discussions for its coccidiosis treatment, **expecting to complete negotiations with a global animal health company in 1H 2025**.

Exploration of Avian Influenza Applications:

December 2024: Preliminary studies indicated that ZIVO's proprietary active ingredients could **reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) in poultry**, showcasing the versatility of its algal-derived products.

Commercialization of Algal Biomass:

July 2023: **Initiated sales of Zivolife™**, a proprietary algal biomass product for human consumption, marking ZIVO's entry into the consumer market.

August 2023: Secured a commitment from ZWorldwide to **purchase all Zivolife™ produced over the next 18 months**, with plans to scale production capacity to meet growing demand.



Where ZIVO is Headed?

Nutrition

Algal Biomass
Extracts
Dry Mixes

Strategic Partnerships & Regional Distributors

- ✓ Establish regional distributorships
- ✓ Find partners to create new marketing channels, products

Production & Global Supply Chain

- ✓ Recruit agribusinesses globally as licensed growers
- ✓ Establish global supply chain with QC compliance
- ✓ Expand algae production in LATAM and North America

Product Development & Compliance

- ✓ Scale-up of Zivolife™
- ✓ Topical skin health ingredient and formulated product launch in U.S., UK pending regulatory approvals

Currently generating revenue and ready to scale up.

Therapeutic

Molecules
Compounds
Complexes

Poultry Digestive Health

- ✓ Prospective licensing or joint development deal
- ✓ Continue refinement of poultry product candidates
- ✓ Finalize product, commercialize successful market entry

Immune Modulating Product

- ✓ Commercial scale ramp-up of bioactive molecules
- ✓ Begin testing in swine and canine models

Intellectual Property Portfolio

- ✓ Targeting 50+ patents pending across the globe

**Patents filed. Tested. Ready to license.
An opportunity for major value inflection.**



Leadership Team



John B. Payne – President and CEO

Served on ZIVO's Board since 2013 and Chairman since 2019. He has a significant management experience in publicly-traded healthcare companies and currently also serves as Chairman of the Board for American Humane and as Vice Chairman of the Board of Regents at Ross University School of Medicine and School of Veterinary Medicine.



Harlan L. Miller III, PhD – VP Technology and Global Supply

Dr. Miller is a recognized expert in algal production systems, previously as Sr. Technology Director - Algenol Biotech, LLC. He manages international farm conversions SuperFarm engineering and global tech support, and also directs cultivation science and product development at Ft. Myers research facility.



Keith R. Marchiando – CFO

25 years of functional experience and technical knowledge in corporate finance, planning, and accounting for manufacturing and technology firms. Mr. Marchiando holds broad responsibilities for all finance functions, HR, legal and IT matters. Mr. Marchiando is also corporate secretary and reporting/compliance officer.



Amy E. Steffek, PhD - Director R&D

Over 20 years in life science startups ranging across clinical/analytic research, study coordination and regulatory compliance. Dr. Steffek manages multiple research studies, analyses and reporting of research findings pertaining to the Company's proprietary, naturally derived compounds and bioactive molecules.



William P. Pfund, MS - VP R&D

Wide-ranging career in Big Pharma, life science startups and contract research orgs. Responsible for all R&D strategies aimed at developing and validating novel therapeutics and product candidates from ZIVO's proprietary bioproducts, leveraging specific expertise in analytical, in vitro, and in vivo sciences.



One Natural Source. Numerous Commercial Opportunities.

Developing novel therapeutics and functional food ingredients to power immune health



Currently Generating Revenue

- DTC launch in June 2023 of Zivolife™, a nutritional supplement for the human green powder and vegan protein markets



Longer-term Valuation Drivers

- Published studies support active therapeutics pipeline addressing billion-dollar opportunities in animal and human treatments through immune and other novel pathways



Robust and Versatile Products

- Numerous commercial applications in animal feed, functional and medical foods, dietary supplements, nutraceuticals and pharmaceuticals

- ✓ Patent-pending for use as an immune modulating candidate that may establish a new class of therapeutic products
- ✓ Potential for numerous therapeutic applications across three global mega-markets: human, livestock and companion animals